Member Info for TrickyEFC

Expected news next is massive

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

As we currently still valued at £15 mill this is massive.

Fail and no damage as fook all of this is currently priced into Solvonis.

However get good results in relation to this blood brain barrier thing and it's off to Venus never mind the moon

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

5. In-vitro screening for SERT, DAT, and NET release - Evotec appointed by Awakn to lead key preclinical testing.

To ensure the highest standard of preclinical validation, Awakn has appointed Evotec, a globally recognised leader in drug discovery and development, to conduct in-vitro screening for SERT, DAT, and NET release activity.

Evotec brings world-class expertise in:

· Neurotransmitter pharmacology

· High-throughput screening

· Precision drug discovery

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timeline.

6. Preclinical animal testing.

Awakn has previously announced successful preclinical animal testing results for one of the three synthesised candidates. The study demonstrated promising early signs of efficacy, supporting the potential of AWKN-SDN-14 as a next-generation PTSD treatment. These results provide a strong scientific foundation for the next phase of testing.

I Nicko was someone doing 5 million sells as ya say but they stopped Monday am I believe.

08:53:13 27.85 100,000 Unknown* 27.85k O

10-Jul-25 08:52:16 27.85 100,000 Unknown* 27.85k

Reason it was nt to buy?

Was Oberon the only seller we had.

Since Monday those sells have fallen off a cliff

Llama that's a fair amount they will take well it's a large amt.

Mms accumulation for incoming news.

So hope the update on PTSD in Vivo is good as if so this is 💣💣💣💣💣

Hoovers sucking up till we blow 🔥🔥

Nothing sticks 🫣grrr

I may put me hoover on soon and see what I can suck up

Let's get rolling bones.

Into the 3s

Was perfect peters 1 to 10 as bad as this nob head.

Where's that filter button

Next drug patent cliff to challenge Big Pharma strategy https://share.google/IgOPlQliaboiZHjwd

The UT yesterday and given it was 255 to sell at close yesterday

Can now sell close to28

Could be one last Oberon dump to flush holding it up

So massive am sceptical somewhat. Got to be in it to win it though.

evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning awkn-sdn-14's therapeutic potential.

i believe if they can jump this blood brain hurdle 👀👀 will be on is like **** on a goose

evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning awkn-sdn-14's therapeutic potential.

While we mainly have our eyes on the lead product this month we get results on SVN 14 PTSD product.

This would be absolutely massive to get positive results in this field as well.

If this is good I expect the market will have to take this into overdrive to get a fair value.

In-vitro screening for SERT, DAT, and NET release - Evotec appointed by Awakn to lead key preclinical testing.

To ensure the highest standard of preclinical validation, Awakn has appointed Evotec, a globally recognised leader in drug discovery and development, to conduct in-vitro screening for SERT, DAT, and NET release activity.

Evotec brings world-class expertise in:

· Neurotransmitter pharmacology

· High-throughput screening

· Precision drug discovery

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timeline

Dv or was that 5k you 😜

One of two things will happen in next 80mins

Nothing or we have a lil pop.

The buying yesterday and today has been to strong